Xencor XNCR 深 沪
等待开盘 12-15 09:30:00 美东时间
16.52
-0.540
-3.17%
华盛通- 最 高17.14
- 今 开17.02
- 成交量 50.75万股
- 最 低 16.435
- 昨 收 17.06
- 总市值 11.78亿
- 52周最高 24.94
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.92
- 委 比 -64.81%
- 总股本 7132.30万
- 历史最高 58.345
- 量 比 0.61
- 振 幅 4.13%
- 历史最低 5.75
- 每 手 1
- 风险率 4.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which
12-09 20:11
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Submits Recalculated Initial Offer of $4.75 Based on Board's Value Destructive Actions Nominated Two Independent Candidates to Restore Oversight and Protect Shareholders Urges Shareholders t...
12-03 07:48
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $29
Truist Securities analyst Gregory Renza initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $29.
11-25 02:04
Candel pausing development of CAN-2409 in prostate cancer type
Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing. The company...
11-15 00:47
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $42
Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $40 to $42.
11-06 22:52
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Barclays Upgrades Xencor to Overweight, Raises Price Target to $23
Barclays analyst Etzer Darout upgrades Xencor (NASDAQ:XNCR) from Underweight to Overweight and raises the price target from $6 to $23.
10-29 20:11
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
